MS Research Incubator Grants Announcement

Four new projects address MS Australia’s priorities for MS research, including causes and prevention, better treatments and cures via repair and regeneration of cells.

MS Research Incubator Grants Announcement

Four new projects address MS Australia’s priorities for MS research, including causes and prevention, better treatments and cures via repair and regeneration of cells.

Together with the broader sector, we are concerned by the decision relating to pricing for therapy supports, support coordination and plan management.

The price is not right! NDIS pricing failure hurts sector and the disability community

Together with the broader sector, we are concerned by the decision relating to pricing for therapy supports, support coordination and plan management.

Living well with MS

MS Australia’s new wellness resources offer clear, evidence-informed guidance to support lifestyle decisions related to MS.

Living well with MS

MS Australia’s new wellness resources offer clear, evidence-informed guidance to support lifestyle decisions related to MS.

The Neurological Alliance Australia (NAA) is calling for the establishment of a Taskforce for Neurological Conditions, to urgently address the needs of millions of forgotten Australians.

Count Us In

The Neurological Alliance Australia (NAA) is calling for the establishment of a Taskforce for Neurological Conditions, to urgently address the needs of millions of forgotten Australians.

Global multiple sclerosis prevention initiative underway

MS Canada and MS Australia lead new global initiative into the prevention and ultra-early detection of MS

Global multiple sclerosis prevention initiative underway

MS Canada and MS Australia lead new global initiative into the prevention and ultra-early detection of MS

Nominations now open

MS Australia Awards

Nominations now open

3-5 December 2025
Sofitel Brisbane Central

MS Australia Research Conference 2025

3-5 December 2025
Sofitel Brisbane Central

EBV in MS

The goal of the EBV in MS Platform is to better understand the role of EBV in the development of MS and in ongoing disease; and the potential to target EBV to prevent or treat MS

EBV in MS

The goal of the EBV in MS Platform is to better understand the role of EBV in the development of MS and in ongoing disease; and the potential to target EBV to prevent or treat MS

“PLATYPUS” - PLatform Adaptive Trial for remYelination and neuroProtection in mUltiple Sclerosis - multi-arm, multi-stage (MAMS) clinical trial which will test two repurposed drugs to help people living with progressive MS. 

PLATYPUS

“PLATYPUS” - PLatform Adaptive Trial for remYelination and neuroProtection in mUltiple Sclerosis - multi-arm, multi-stage (MAMS) clinical trial which will test two repurposed drugs to help people living with progressive MS. 

Our mission: a world without MS

MS News

30 July 2025

MS Australia announces the four recipients of the first round of Incubator Grants for 2025….
Media Release

30 July 2025

A world-first Australian study is using DNA to identify a person’s genetic risk of developing multiple sclerosis (MS) to understand…
MS News

29 July 2025

MS Australia is calling on the government to improve the aged care system to better meet the needs of older…
MS News

29 July 2025

CEO Rohan Greenland reveals the upcoming launch of a national blueprint for neurological conditions, designed to prompt the Australian Government…
MS News

29 July 2025

Consistently high antibodies to a specific protein of the Epstein-Barr virus may predict MS years before disease onset….

22 July 2025

Dr Fiona McKay is joined by MS experts, Dr Olivia Wills, Dr Steven Petratos and Dr Izanne Roos, to discuss…

8 July 2025

Jeremy Henderson is joined by MS Queensland CEO David Curd and Ambassador, Rachel Kerr, to discuss the incredible MS Readathon…

30 June 2025

Jeremy Henderson is joined by the National President of the Australian Physiotherapy Association and the CEOs of MSWA, Dietitians Australia…
MS News

26 June 2025

The Pharmaceutical Benefits Advisory Committee has recommended ublituximab (Briumvi®) be listed on the PBS for treating relapsing remitting MS….
MS News

24 June 2025

CEO Rohan Greenland responds to the latest NDIS pricing decision, warning it threatens access to essential therapies and places additional…
Read More

Newsletter subscription

  • Enter your details

Home